In early trading of US stocks on Wednesday, the stock price of Regenerative Pharmaceuticals, a component of the S&P 500 index, rose 6.7%. The company is witnessing an increase in revenue from its core products. Currently, this increase has offset the decline in its previous major drug revenue. Analysts say renewable energy is worth buying.

Zhitongcaijing · 10/01/2025 14:25
In early trading of US stocks on Wednesday, the stock price of Regenerative Pharmaceuticals, a component of the S&P 500 index, rose 6.7%. The company is witnessing an increase in revenue from its core products. Currently, this increase has offset the decline in its previous major drug revenue. Analysts say renewable energy is worth buying.